Updated September 2026Three molecules, one checkableKin Meds review
One figure can be checked against a manufacturer's own published price. Two cannot, and sit at about half cash-pay.
The verdict
One of Kin Meds' three figures can be checked against the manufacturer that supplies it, and two cannot. The orforglipron price matches LillyDirect's own published starter rate, which is a rare thing on this subject: a number a reader can verify without trusting the seller. The other two sit at roughly half what those channels charge for cash, and nothing on the pages explains who reaches them.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Orforglipron · Semaglutide · Tirzepatide
- Form
- Injection · Oral
- From
- $149/mo
- Prescription
- Required
- Compounded
- No
Kin Meds prices three molecules, which is one more than nearly any seller here carries. Orforglipron is the newest and rarely carries a published figure at all. The lines reference the manufacturers' own direct channels.
Who writes the prescription, and what do they see?
A prescription is arranged before dispensing and the fulfillment runs through manufacturer channels. What is not stated is the condition attached to the two low figures. Whether a buyer reaches them depends on insurance or a savings card. The pages do not say which, or who qualifies.
The service is an access route to manufacturer products rather than a compounding operation. That has a real advantage: these are approved, FDA-reviewed products. It also has a consequence. The price a buyer meets is set by a program they may not be eligible for.
What happens when the dose goes up?
Nothing is published about what these figures become at a higher dose, and on manufacturer-supplied products that is largely the manufacturer's schedule rather than Kin Meds'. The pages do not point a reader to where it is published.
What the price includes
Verifiability is the axis this seller should be judged on. One figure agrees with its own supplier's published rate and can be confirmed in a minute. Two sit far under what those same suppliers charge a cash buyer, which means a condition applies, and the pages name neither the condition nor who satisfies it. A first-order discount is disclosed separately and affects one bill rather than the standing rate.
What it claims, and what it cites
These lines reference approved products supplied through manufacturer channels rather than compounded preparations. An approved product has been reviewed by the FDA for safety and quality, which the compounded lines elsewhere on this site have not.
Where it holds up, and where it does not
- Strength: One figure can be checked against its source
- Strength: A rarely priced molecule appears at all
- Strength: The supplying channel is identified
- Limitation: Two figures carry an unnamed condition
- Limitation: Eligibility is never described
- Limitation: The published rate sits far under cash pay
- Limitation: Coverage is nowhere enumerated
What the evidence says about this kind of treatment
The assessment above is about Kin Meds. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader pricing orforglipron, which almost no seller publishes a figure for.
- Wrong for
- A reader assuming the semaglutide and tirzepatide figures are cash-pay prices.
How Kin Meds compares
| Seller | Who it suits | Go |
|---|---|---|
| FORM | Readers who already know the manufacturer price and want a named route to a prescriber | See FORM → |
 PreventiveMD | A reader interested in orforglipron, which most sellers in this category do not offer at all. | See PreventiveMD → |
 Found | Readers who will prepay a year and want coaching and membership inside one figure | See Found → |
More GLP-1 telehealth sellers reviews: Go Vida PlenaGobyMedsGoldspan HealthGood Girl RxGood Life MedsGreen Cap Health
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Will I pay $199 for semaglutide?
- Only if the tier applies to you. NovoCare's cash-pay standard pen is $299 a month, and the condition behind the lower figure is not published.
- What is orforglipron?
- A newer GLP-1 sold as Foundayo through LillyDirect. Kin Meds' $149 matches that channel's published starter cash price, making it the most checkable figure here.
- Are these compounded?
- No. The lines reference manufacturer channels supplying approved products, which have been FDA-reviewed.
- Is Kin Meds expensive compared with other GLP-1 telehealth sellers?
- Kin Meds publishes a starting figure of $199/mo. Across the 83 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $179, which puts Kin Meds above the median. The other 5 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.